Finance

Lists
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
US$ ३.४२
-०.५८%
(-०.०२०) 1D
US$ ३.४२
०.००% (०.००)
After hours
Closed: अक्टोबर ८, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
US$ ३.४३
High
US$ ३.४३
Low
US$ ३.२७
Mkt. cap
२७.४२ करोड
Avg. vol.
६.६२ लाख
Volume
५.६६ लाख
52-wk high
US$ १४.८७
52-wk low
US$ ३.२७
EPS
-US$ ३.०४
Shares outstanding
८.०२ करोड
No. of employees
८८
Open
US$ ३.४३
High
US$ ३.४३
Low
US$ ३.२७
Mkt. cap
२७.४२ करोड
Avg. vol.
६.६२ लाख
Volume
५.६६ लाख
52-wk high
US$ १४.८७
52-wk low
US$ ३.२७
EPS
-US$ ३.०४
Shares outstanding
८.०२ करोड
No. of employees
८८
News stories
From web sources and news partners
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees८८
Founded२०१६
HeadquartersSouth San Francisco, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websitebbotx.com
Analyst ratings
Based on 9 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current US$ ३.४२
US$ २५.०० (+६३०.९९%)
Average
US$ २१.०० (+५१४.०४%)
Lowest
US$ १५.०० (+३३८.६०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Berens
Leerink Partners
Buy
Reiterated
US$ २५.००
+६३१%
09/18/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Unknown Analyst
Wedbush
Buy
Maintained
US$ २५.००
+६३१%
09/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$ २१.००
+५१४%
09/09/2026
Sean McCutcheon
Raymond James
Buy
Maintained
US$ २२.००
+५४३.३%
09/09/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
US$ १५.००
+३३८.६%
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
US$ २०.००
+४८४.८%
09/09/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
US$ १८.००
+४२६.३%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
US$ २५.००
+६३१%
08/14/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
US$ २२.००
+५४३.३%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
US$ २५.००
+६३१%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
US$ २२.००
+५४३.३%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ २९.००
+७४८%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
३.५१ करोड
३.८१ करोड
३.९८ करोड
४.९२ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.४१ करोड
५३.३४ लाख
६३.७७ लाख
१.१० करोड
Operating expense
४.९२ करोड
४.३४ करोड
४.६२ करोड
६.०२ करोड
Total operating expenses
४.९२ करोड
४.३४ करोड
४.६२ करोड
६.०२ करोड
Operating income
-४.९२ करोड
-४.३४ करोड
-४.६२ करोड
-६.०२ करोड
Other non operating income
९.८० लाख
१.८७ लाख
१.२९ लाख
१.८२ लाख
EBT including unusual items
-४.४८ करोड
-३.८८ करोड
-४.२१ करोड
-५.६५ करोड
EBT excluding unusual items
-४.४८ करोड
-३.८८ करोड
-४.२१ करोड
-५.६५ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-४.४८ करोड
-३.८८ करोड
-४.२१ करोड
-५.६५ करोड
Net profit margin
-
-
-
-
Earnings per share
-१.०३
-०.४९
-०.५३
-०.७१
Interest and investment income
३४.४४ लाख
४४.२४ लाख
३९.४४ लाख
३५.५१ लाख
Interest expense
-
-
-
-
Net interest expenses
३४.४४ लाख
४४.२४ लाख
३९.४४ लाख
३५.५१ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-४.९१ करोड
-४.३३ करोड
-४.६१ करोड
-६.०१ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू